Amgen Gains as Cancer Drug ‘Steals the Show’ From Legacy Woe

(Bloomberg) -- Shares of Amgen Inc. rose as much as 5.2% on Wednesday after early results from an experimental therapy showed promise in colon cancer and drew attention away from earnings and fears...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.